Stephen Summerow
Optometrist · Perry, GANPI 1912039595
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $151,813 of the $222,271 with a category attached, or 68.3%. 22 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 44.5% of the total. 2025 is the largest year on record at $63,312, 2.6 times the $23,895 reported in 2019. Among optometrist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 541 payments — averaging $410.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$99K
- Harrow Eye, LLC$37K
- AbbVie$30K
- Novartis$15K
- Alcon$14K
- Shire North American Group Inc$13K
- plus $14K from 16 others
What the payments were for
- Consulting fees$15,9407%
- Speaking & faculty fees$151,81368%
- Travel & lodging$36,76317%
- Food & beverage$17,7558%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 195 | $99,014 |
| Harrow Eye, LLC | 36 | $37,340 |
| AbbVie(2 entities) | 85 | $29,833 |
| Novartis | 39 | $15,466 |
| Alcon | 42 | $13,937 |
| Shire North American Group Inc | 31 | $13,046 |
| Kala Pharmaceuticals, Inc. | 29 | $10,161 |
| Tarsus Pharmaceuticals, Inc. | 15 | $677 |
| Oyster Point Pharma, Inc. | 12 | $469 |
| Amgen | 13 | $442 |
| Bausch & Lomb Americas Inc. | 13 | $349 |
| Eyevance Pharmaceuticals LLC | 5 | $328 |
| Dompe US, Inc. | 8 | $309 |
| Johnson & Johnson Vision Care, Inc. | 4 | $280 |
| Sight Sciences, Inc. | 2 | $205 |
| Aerie Pharmaceuticals, Inc. | 2 | $198 |
| Thea Pharma Inc. | 4 | $79 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $43 |
| Akorn Operating Company LLC | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Tearlab Corp | 1 | $24 |
| Coopervision Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$222,271 in reported general payments places this provider in the 95th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TepezzaTeprotumumab-Trbw | 13 | $735,111 |
| RestasisCyclosporine | 167 | $179,035 |
| XiidraLifitegrast | 81 | $91,273 |
| CequaCyclosporine | 66 | $63,023 |
| LumiganBimatoprost | 138 | $54,034 |
| XdemvyLotilaner | 20 | $38,084 |
| TyrvayaVarenicline Tartrate | 32 | $20,744 |
| Cyclosporine | 38 | $17,578 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $13,336 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,546 |
| Travoprost | 69 | $8,873 |
| VyzultaLatanoprostene Bunod | 22 | $7,889 |
| Alphagan PBrimonidine Tartrate | 29 | $5,912 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,819 |
| Loteprednol Etabonate | 19 | $2,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTepezza | $442 | $735,11113 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $29,833 | $252,317365 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $349 | $109,708117 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $99,014 | $63,02366 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $677 | $38,08420 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $469 | $20,74432 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $43 | $2,73719 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $328 | $2,54511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,285 optometrist providers in Georgia.
Other optometrist in Perry
- Joshua JohnstonAtlanta$993K
- John WomackCanton$931K
- Naheed AhmadRoswell$296K
- Scott MoscowRoswell$278K
- Janelle DavisonSmyrna$199K
- Keyle BrownDawsonville$182K
- Nacondus GambleFort Stewart$175K
- Amber ZaunbrecherAtlanta$99K
- Jeffrey CofieWarner Robins$93K
- Emily LoveAtlanta$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.